Nifurtimox (Lampit, BAYA2502)

DRUG3 trials

Sponsors

Bayer

Conditions

Chagas DiseaseChagas' Disease

Phase 1

Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study

CompletedNCT03334838

BayerChagas' Disease

Start: 2019-06-10End: 2020-01-29Updated: 2020-12-30

Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg

CompletedNCT03350295

BayerChagas Disease

Start: 2018-06-14End: 2018-12-14Updated: 2019-12-12

Phase 3

A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi

CompletedNCT02625974

BayerChagas Disease

Start: 2016-01-27End: 2021-08-10Updated: 2024-08-19

Related Papers

ELISA F29 –A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment

PLoS neglected tropical diseases2023-06-236 citations

2128. Lack of Congenital Transmission in Infants Born of Female Patients with Chagas Disease who Became Pregnant During a Nifurtimox Study (CHICO and CHICO SECURE Study)

Open Forum Infectious Diseases2022-12-011 citations

Clinical investigation of the biopharmaceutical characteristics of nifurtimox tablets – Implications for quality control and application

European Journal of Pharmaceutical Sciences2021-07-1215 citations

Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)

PLoS neglected tropical diseases2021-01-0745 citations